Lycia Therapeutics
Developing first-in-class therapeutics that degrade extracellular proteins to address difficult-to-treat diseases.
Launch date
Employees
Market cap
-
Enterprise valuation
CAD581—872m (Dealroom.co estimates May 2024.)
South San Francisco California (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
$50.0m | Early VC | ||
$70.0m | Series B | ||
* | $107m | Series C | |
| Total Funding | CAD309m | ||
Recent News about Lycia Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.